New Zealand medicinal cannabis company Helius Therapeutics has appointed Angela Freiden as its new director of innovation and productivity.
Freiden will be responsible for co-ordinating innovative projects and products, developing and growing collaborations in New Zealand and globally, leading funding applications and ensuring the development and timely delivery of next-generation medicines.
Chief executive Carmen Doran said: “Angela will be responsible for driving continuous improvement and innovative in-house processes. This will ensure Helius delivers products in the most efficient way possible, shortening lead times and lessening costs.”
“Like many others at Helius, Angela also brings considerable animal health experience, which will be a huge asset for our sister company Hale Animal Health as it continues to develop its R&D pipeline for the future.”
Freiden holds an MBA in health administration and was previously general manager and non-executive director at New Beta and New Alpha Innovation, developing biopharmaceutical products for humans and animals.
Helius recently appointed Candace Kinser as its new chair and Martin Vos as its new director of research & development.